Reducing the risk of secondary malignancies in lymphoma
2 years on: Deborah discusses her venetoclax trial and becoming MRD negative
Deborah Henderson et al.
What can clonal evolution in chronic lymphocytic leukemia (CLL) tell us about outcomes?
Clinical evidence supporting rituximab
Won Seog Kim
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow